Difference between revisions of "Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)"
Jump to navigation
Jump to search
m |
|||
| Line 9: | Line 9: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=All lines of therapy= | =All lines of therapy= | ||
==Vismodegib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ==Vismodegib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:392a4b|Variant=1}}=== | ===Regimen {{#subobject:392a4b|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 24: | Line 23: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Eligibility criteria==== | ====Eligibility criteria==== | ||
*SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations | *SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations | ||
| + | </div> | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Vismodegib (Erivedge)]] 150 mg PO once per day | *[[Vismodegib (Erivedge)]] 150 mg PO once per day | ||
| − | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312 PubMed] NCT02091141 | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312 PubMed] NCT02091141 | ||
| − | |||
[[Category:SMO or PTCH-1 (Hedgehog) regimens]] | [[Category:SMO or PTCH-1 (Hedgehog) regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Malignant solid neoplasm]] | [[Category:Malignant solid neoplasm]] | ||
[[Category:Site-agnostic regimens]] | [[Category:Site-agnostic regimens]] | ||
Revision as of 13:17, 23 January 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Vismodegib monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a |
Eligibility criteria
- SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141